Achilles Therapeutics PLC
(NAS:ACHL)
$
1.0262
0.0062 (0.61%)
Market Cap: 43.82 Mil
Enterprise Value: -46.83 Mil
PE Ratio: 0
PB Ratio: 0.37
GF Score: 38/100 Achilles Therapeutics PLC to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting - Fireside Chat Transcript
Apr 14, 2022 / 02:30PM GMT
Release Date Price:
$2.37
(-7.78%)
Lee M. Stern
Achilles Therapeutics plc - VP of IR & External Communications
Presentations from the 2022 AACR Annual Meeting - Fireside Chat
Apr 14, 2022 / 02:30PM GMT
=====================
Corporate Participants
=====================
* Charles Swanton
Achilles Therapeutics plc - Founder
* Iraj Ali
Achilles Therapeutics plc - CEO & Director
* Lee M. Stern
Achilles Therapeutics plc - VP of IR & External Communications
* Sergio A. Quezada
Achilles Therapeutics plc - Founder & Chief Scientific Officer
=====================
Conference Call Participants
=====================
* Joseph Michael Catanzaro
Piper Sandler & Co., Research Division - Director & Senior Biotech Analyst
=====================
-
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot